
David G Hicks

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11255239/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 2013, 31, 3997-4013.	0.8	3,276
2	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology, 2010, 28, 2784-2795.	0.8	2,667
3	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Archives of Pathology and Laboratory Medicine, 2014, 138, 241-256.	1.2	961
4	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). Archives of Pathology and Laboratory Medicine, 2010, 134, e48-e72.	1.2	855
5	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Archives of Pathology and Laboratory Medicine, 2010, 134, 907-922.	1.2	697
6	Mechanisms of TNF-α– and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. Journal of Clinical Investigation, 2003, 111, 821-831.	3.9	489
7	The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer: Basic and Clinical Research, 2010, 4, 35-41.	0.6	415
8	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2015, 33, 2695-2704.	0.8	279
9	Mechanisms of TNF-α– and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. Journal of Clinical Investigation, 2003, 111, 821-831.	3.9	271
10	Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR. American Journal of Surgical Pathology, 2006, 30, 1097-1104.	2.1	229
11	Genetic Heterogeneity in <i>HER2</i> Testing in Breast Cancer: Panel Summary and Guidelines. Archives of Pathology and Laboratory Medicine, 2009, 133, 611-612.	1.2	211
12	Recommendations for Improved Standardization of Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 124-133.	0.6	205
13	The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer: Basic and Clinical Research, 2010, 4, 117822341000400.	0.6	199
14	Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Human Pathology, 2005, 36, 250-261.	1.1	157
15	The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clinical Cancer Research, 2005, 11, 186-92.	3.2	138
16	HER2+ Breast Cancer. American Journal of Clinical Pathology, 2008, 129, 263-273.	0.4	130
17	The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast. American Journal of Surgical Pathology, 2005, 29, 1221-1227.	2.1	119
18	Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2008, 16, 513-520.	0.6	118

#	Article	IF	CITATIONS
19	Molecular Classification of Breast Carcinomas by Immunohistochemical Analysis. Diagnostic Molecular Pathology, 2009, 18, 125-132.	2.1	109
20	Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues. Journal of the National Cancer Institute, 2012, 104, 1815-1824.	3.0	103
21	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast. Archives of Pathology and Laboratory Medicine, 2014, 138, 595-601.	1.2	94
22	Loss of Breast Cancer Metastasis Suppressor 1 Protein Expression Predicts Reduced Disease-Free Survival in Subsets of Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 6702-6708.	3.2	92
23	Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). Journal of Bone and Mineral Research, 2012, 27, 79-92.	3.1	89
24	Delay to formalin fixation †̃cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry. Modern Pathology, 2013, 26, 1-9.	2.9	88
25	Primary lymphoma of bone. Correlation of magnetic resonance imaging features with cytokine production by tumor cells. Cancer, 1995, 75, 973-980.	2.0	80
26	Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine. Archives of Pathology and Laboratory Medicine, 2019, 143, 1346-1363.	1.2	78
27	Fluorescence In Situ Hybridization (FISH) as Primary Methodology for the Assessment of HER2 Status in Adenocarcinoma of the Breast. Diagnostic Molecular Pathology, 2007, 16, 207-210.	2.1	73
28	Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Modern Pathology, 2015, 28, 921-931.	2.9	70
29	A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer. Cancer Investigation, 2010, 28, 978-982.	0.6	65
30	The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: A fluorescence in situ hybridization study. Human Pathology, 2005, 36, 348-356.	1.1	61
31	Shared phenotypic expression of osteoblasts and chondrocytes in fracture callus. Journal of Bone and Mineral Research, 1995, 10, 533-544.	3.1	61
32	HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles. Modern Pathology, 2022, 35, 1075-1082.	2.9	53
33	Differential regulation of type-II and type-X collagen synthesis by parathyroid hormone-related protein in chick growth-plate chondrocytes. Journal of Orthopaedic Research, 1997, 15, 162-174.	1.2	52
34	Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time. Laboratory Investigation, 2015, 95, 334-341.	1.7	52
35	Expression of the Androgen Receptor and its Correlation with Molecular Subtypes in 980 Chinese Breast Cancer Patients. Breast Cancer: Basic and Clinical Research, 2012, 6, BCBCR.S8323.	0.6	51
36	Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2016, 34, 4390-4397.	0.8	51

#	Article	IF	CITATIONS
37	Trastuzumab as Adjuvant Therapy for Early Breast Cancer: The Importance of Accurate Human Epidermal Growth Factor Receptor 2 Testing. Archives of Pathology and Laboratory Medicine, 2008, 132, 1008-1015.	1.2	49
38	Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Research and Treatment, 2007, 102, 19-30.	1.1	48
39	A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. Laboratory Investigation, 2014, 94, 467-474.	1.7	48
40	Breast Cancer Metastasis Suppressor-1 Differentially Modulates Growth Factor Signaling. Journal of Biological Chemistry, 2008, 283, 28354-28360.	1.6	46
41	Extraosseous primary and recurrent giant cell tumors: Transforming growth factor-β1 and -β2 expression may explain metaplastic bone formation. Human Pathology, 1996, 27, 625-632.	1.1	43
42	Epithelioid osteosarcoma of bone immunocytochemical evidence suggesting divergent epithelial and mesenchymal differentiation in a primary osseous neoplasm. Cancer, 1993, 71, 2977-2982.	2.0	41
43	HER2-Low Breast Cancers. American Journal of Clinical Pathology, 2022, 157, 328-336.	0.4	39
44	The Expression of the Cytoskeletal Focal Adhesion Protein Paxillin in Breast Cancer Correlates with HER2 Overexpression and May Help Predict Response to Chemotherapy: A Retrospective Immunohistochemical Study. Breast Journal, 2007, 13, 130-139.	0.4	37
45	Solitary Fibrous Tumor of the Breast and Mammary Myofibroblastoma: The Same Lesion?. Breast Journal, 2008, 14, 287-292.	0.4	36
46	HER2 Testing and Subsequent Trastuzumab Treatment for Breast Cancer in a Managed Care Environment. Oncologist, 2009, 14, 760-768.	1.9	35
47	Bone morphogenetic protein-7 in growth-plate chondrocytes: Regulation by retinoic acid is dependent on the stage of chondrocyte maturation. Journal of Orthopaedic Research, 1998, 16, 247-255.	1.2	34
48	Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry. Laboratory Medicine, 2011, 42, 459-467.	0.8	32
49	Reply to E.A. Rakha et al. Journal of Clinical Oncology, 2015, 33, 1302-1304.	0.8	31
50	HER2 Testing in Gastric and Gastroesophageal Junction Cancers. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 506-508.	0.6	30
51	Applying the New Guidelines of HER2 Testing in Breast Cancer. Current Oncology Reports, 2020, 22, 51.	1.8	30
52	Interleukin-10 inhibits cytokine synthesis in monocytes stimulated by titanium particles: Evidence of an anti-inflammatory regulatory pathway. Journal of Orthopaedic Research, 1998, 16, 697-704.	1.2	26
53	P-glycoprotein expression in cartilaginous tumors. , 1997, 65, 95-105.		25
54	Automation of Manual Components and Image Quantification of Direct Dual Label Fluorescence In Situ Hybridization (FISH) for HER2 Gene Amplification. Applied Immunohistochemistry and Molecular Morphology, 2006, 14, 436-440.	0.6	24

#	Article	IF	CITATIONS
55	Breast Cancer Predictive Factor Testing: The Challenges and Importance of Standardizing Tissue Handling. Journal of the National Cancer Institute Monographs, 2011, 2011, 43-45.	0.9	24
56	American Society of Clinical Oncology/College of American Pathologists Human Epidermal Growth Factor Receptor 2 Testing Clinical Practice Guideline Upcoming Modifications: Proof That Clinical Practice Guidelines Are Living Documents. Archives of Pathology and Laboratory Medicine, 2015, 139, 970-971.	1.2	23
57	HER2-low breast cancers: Current insights and future directions. Seminars in Diagnostic Pathology, 2022, 39, 305-312.	1.0	20
58	A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. Breast, 2006, 15, 728-735.	0.9	19
59	Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression. Histopathology, 2014, 65, 508-516.	1.6	18
60	A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study. BMC Cancer, 2018, 18, 1266.	1.1	17
61	Osteoclastlike giant cell tumor of the salivary gland. Annals of Diagnostic Pathology, 2009, 13, 114-118.	0.6	14
62	Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies. Journal of Biomedical Optics, 2019, 24, 1.	1.4	14
63	Risk stratification of ERâ€positive breast cancer patients: A multiâ€institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX ® recurrence score <26. Cancer Medicine, 2019, 8, 4176-4188.	1.3	13
64	In situ hybridization in the pathology laboratory: General principles, automation, and emerging research applications for tissue-based studies of gene expression. Journal of Molecular Histology, 2004, 35, 595-601.	1.0	12
65	Dual expression of α-tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of α-tocopherol-associated protein in estrogen-receptor-positive breast carcinomas. Modern Pathology, 2009, 22, 770-775.	2.9	12
66	Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing. American Journal of Clinical Pathology, 2021, 155, 781-792.	0.4	11
67	Expression of Androgen Receptor and Its Association With Estrogen Receptor and Androgen Receptor Downstream Proteins in Normal/Benign Breast Luminal Epithelium. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 498-504.	0.6	10
68	Regulation of osteoclastic activity in infection. Methods in Enzymology, 1994, 236, 47-58.	0.4	9
69	Immunohistochemistry in the Diagnostic Evaluation of Breast Lesions. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 501-505.	0.6	9
70	p53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer. Human Pathology, 2017, 68, 22-25.	1.1	9
71	Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma. American Journal of Clinical Pathology, 2019, 151, 461-468.	0.4	9
72	Significance of HER2 in Microinvasive Breast Carcinoma. American Journal of Clinical Pathology, 2021, 156, 155-165.	0.4	9

#	Article	IF	CITATIONS
73	HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon's Perspective. Annals of Surgical Oncology, 2008, 15, 1677-1688.	0.7	8
74	Frequency, Clinicopathologic Characteristics, and Follow-up of HER2-Positive Nonpleomorphic Invasive Lobular Carcinoma of the Breast. American Journal of Clinical Pathology, 2020, 153, 583-592.	0.4	8
75	L1CAM Expression in Recurrent Estrogen Positive/HER2 Negative Breast Cancer: A Novel Biomarker Worth Considering. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 287-292.	0.6	7
76	Benign Inclusion of Axillary Lymph Nodes: Report of Two Cases and Literature Review. Breast Journal, 2009, 15, 664-665.	0.4	6
77	Progress in Implementing HER2 Testing Guidelines. Archives of Pathology and Laboratory Medicine, 2014, 138, 863-864.	1.2	6
78	Expression of a-Tocopherol-Associated protein (TAP) is associated with clinical outcome in breast cancer patients. BMC Clinical Pathology, 2015, 15, 21.	1.8	6
79	Molecular Pathology and Pre-Analytic Variables: Impact on Clinical Practice From a Breast Pathology Perspective. Current Pathobiology Reports, 2018, 6, 125-134.	1.6	5
80	The Role of the Indispensable Surgical Pathologist in Treatment Planning for Breast Cancer. Archives of Pathology and Laboratory Medicine, 2008, 132, 1226-1227.	1.2	5
81	Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach. Human Pathology Reports, 2021, 26, 300574.	0.1	5
82	Standardization of Tissue Handling From the OR to the Laboratory. AORN Journal, 2014, 99, 810-813.	0.2	4
83	Breast and Prostate Cancer in a BRCA2 Carrier. Breast Journal, 2012, 18, 511-513.	0.4	3
84	The Impact of Pre-analytic Variables on Tissue Quality from Clinical Samples Collected in a Routine Clinical Setting: Implications for Diagnostic Evaluation, Drug Discovery, and Translational Research. Methods in Pharmacology and Toxicology, 2014, , 259-270.	0.1	3
85	Reply to R. Bhargava et al and K. Lambein et al. Journal of Clinical Oncology, 2014, 32, 1857-1859.	0.8	3
86	p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?. Human Pathology, 2016, 55, 196-201.	1.1	3
87	Core vs Breast Resection Specimen: Does It Make a Difference for HER2 Results?. American Journal of Clinical Pathology, 2015, 144, 533-535.	0.4	2
88	Reconsidering "lowâ€risk―criteria for breast cancer recurrence in hormone positive patients. Breast Journal, 2019, 25, 545-547.	0.4	2
89	HER2 Testing. Applied Immunohistochemistry and Molecular Morphology, 2021, Publish Ahead of Print, 635-642.	0.6	2
90	Preanalytic Variables, Tissue Quality and Clinical Samples from Breast Cancer Patients: Implications		2

for Treatment Planning, Drug Discovery and Translational Research. , 2016, , 19-26.

#	Article	IF	CITATIONS
91	Hormone Receptors (ER/PR). , 2016, , 430-439.		1
92	Targeted therapies in breast cancer: tailoring treatment to the molecular drivers of disease progression. Medical Laboratory Observer, 2012, 44, 36, 38-9.	0.1	1
93	Predictive Biomarkers in Breast Cancer: ER, PR and Her-2/neu. , 2015, , 217-233.		0
94	In Reply. Archives of Pathology and Laboratory Medicine, 2016, 140, 741-741.	1.2	0
95	Breast and Gynecologic Tumors. , 2021, , 89-120.		0
96	HER2-Positive Carcinoma. , 2016, , 350-359.		0
97	Carcinoma With Extensive Intraductal Component. , 2016, , 382-385.		0
98	HER2., 2016,, 440-451.		0
99	Myofibroblastoma. , 2016, , 518-525.		0
100	Introduction: Prognostic and Predictive Factors. , 2016, , 386-393.		0
101	Breast Carcinoma, Male. , 2016, , 660-663.		0
102	Hereditary Breast/Ovarian Cancer Syndrome: *BRCA2*. , 2016, , 650-653.		0
103	Invasive Lobular Carcinoma Variants. , 2016, , 258-263.		0
104	Expression Profiling, Protein. , 2016, , 486-493.		0
105	Expression Profiling, mRNA. , 2016, , 474-477.		0
106	Basal-Like Carcinoma. , 2016, , 324-331.		0
107	Metastatic Disease to the Musculoskeletal System. , 2006, , 7-16.		0
108	Abstract P4-05-09: Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience. Cancer Research, 2022, 82, P4-05-09-P4-05-09.	0.4	0

#	Article	IF	CITATIONS
109	Detailed Morphologic Evaluation of Breast Papillary Lesions on Core Biopsy Is Critical for Accurate Classification and Clinical Management: The Experience of an Academic Institute. Clinical Breast Cancer, 2021, , .	1.1	0